针对阿尔茨海默病的血基生物标志物的临床实施建议
Michelle M Mielke1, Matthew Anderson2, J Wesson Ashford3,4
1Department of Epidemiology and Prevention, Wake Forest University School of Medicine, Winston-Salem, USA.
概括
基于血液的生物标志物 (BBM) 提供了一个具有成本效益和可访问的阿尔茨海默病 (AD) 诊断工具. 建议将这些生物标志物纳入临床实践,以改善患者获得治疗的机会.
科学领域:
- 神经学 神经学
- 生物标志物发现发现
- 临床诊断 临床诊断 临床诊断
背景情况:
- 阿尔茨海默病 (AD) 诊断传统上依赖于昂贵和侵入性的方法,如PET扫描和CSF分析.
- 疾病修饰治疗 (DMT) 的出现需要可扩展和可访问的方法来确认粉样蛋白病理.
- 基于血液的生物标志物 (BBM) 为AD生物标志物测试提供了一个有希望的,低成本的替代方案.
研究的目的:
- 为阿尔茨海默病诊断中BBM临床实施提供标准化建议.
- 为当前的选和未来的BBM确认使用建立路径.
- 促进BBM在常规临床实践中的整合.
主要方法:
- 召集一个专门的基于血液的生物标志物工作组,由全球首席执行官倡议对阿尔茨海默病.
- 为BBMs开发两个不同的临床实施途径.
- 提供关于解释BBM测试结果的指导.
主要成果:
- 目前对BBM进行分类和未来确认使用的确定的途径.
- 标准化诊断方法用于BBM解释.
- 展示了BBMs作为AD生物标志物测试的可访问和可扩展的解决方案.
结论:
- 将BBM整合到临床实践中简化了阿尔茨海默病的诊断过程.
- BBM为符合条件的患者提供及时获得疾病修饰治疗的便利.
- BBM代表了在易于使用和成本效益的AD诊断方面取得的重大进步.
关键词:
阿尔茨海默氏症的疾病是阿尔茨海默氏症.氨基化物 氨基化物生物标志物生物标志物基于血液的生物标志物临床实施 临床实施临床实践中的临床实践认知障碍是一种认知障碍.改变疾病的治疗方法.患者的旅程 患者的旅程主要护理是一级医疗保健.这是次要的护理.更多相关视频
06:19Author Spotlight: A Personalized Approach Towards Investigating Alzheimer's Disease Using an In Vitro Blood-Brain Barrier Model
Published on: October 20, 2023
1.9K
04:22Author Spotlight: Exploring Sex-Specific Glial Signatures and Therapeutic Leads for Alzheimer's Disease
Published on: May 20, 2024
779
相关概念视频
01:26Alzheimer's Disease: Overview
451
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
451
01:22Alzheimer's Disease: Treatment
170
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
170